2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride

Catalog No. :
ACXWUD851
CAS No. :
522-48-5
Molecular Formula :
C13H17ClN2
Molecular Weight :
236.75

IUPAC Name:2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride

2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g98%$81.00Login to see priceIn stockInquiry
100g98%$268.00Login to see priceIn stockInquiry
500g98%$1072.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride
IUPAC Name2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride
MDL No.MFCD00058029
Molecular FormulaC13H17ClN2
Molecular Weight236.75
SMILES[H]Cl.C1(C2CCCC3=C2C=CC=C3)=NCCN1
InChI KeyBJORNXNYWNIWEY-UHFFFAOYSA-N
SynonymCareall Eyedrops Original | NSC757339 | NSC-757339 | Tetrahydrozoline hydrochloride [USP] | Tetrahydrozoline hydrochloride | 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride | Family Care Original Eye | Sound Body Original Eye
CAS No.522-48-5
PubChem CID10648

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACXWUD851 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACGUCM904 route compound structure diagram
    ACGUCM90484460-89-9 In Stock
  2. Then
  3. ACXWUD851 route product structure diagram
    ACXWUD851522-48-5 In Stock
Inquiry

2. ACXWUD851 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACXWUD851 route product structure diagram
    ACXWUD851522-48-5 In Stock
Inquiry

Comments (0)